---

Prof Lorraine O’Driscoll is Director of Research & Professor of Pharmacology at the School of Pharmacy and Pharmaceutical Sciences, and the Trinity Biomedical Sciences Institute of Trinity College Dublin. Following her PhD, Prof O’Driscoll undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and the University of Miami. Prior to joining TCD in 2008, Prof O’Driscoll most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU. She has been a Principal Investigator (PI) on 5 cancer clinical trials with Cancer Trials Ireland, and on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and PI and Chair with H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from 27 European countries, 3 US universities, Australia and 7 industry partners. Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer.